Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5552W HIGH $2.05
Volume
78.04 K
Value Traded
1.09 M
Short % Float
8.86%
-3.23%Week
-9.58%1 Month
-17.87%3 Month
-1.04%6 Month
-89.63%5 Year
-89.63%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
84.99 M
EPS (TTM)
-0.18
P/E Ratio
-
Ent. Value
51.12 M
Total Shares
95.09 M
Float Shares
87.38 M
Insiders
8.11%
Institutions
17.44%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CGTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Cognition Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cognition Therapeutics, Inc.
225Total events
10Upcoming
39Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationCT1812Presentation
Presentation of additional analyses from Phase 2 SHIMMER study at AAIC
dementia with Lewy bodies (DLB)source ↗
▲FDA Feedback ReceivedCT1812FDA Meeting
FDA agreed DLB psychosis could be approvable outcome and aligned on key aspects of pivotal trial design
dementia with Lewy bodies (DLB) psychosissource ↗
▲Patent GrantedCT1812IP / Competition
Notice of Allowance for composition of matter patent covering polymorphic crystalline form of zervimesine
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
◆Timing GuidanceCT1812Presentation
FDA formal minutes expected in June 2026
dementia with Lewy bodies with psychosissource ↗
▲FDA Feedback ReceivedCT1812FDA Meeting
FDA meeting minutes received providing alignment on key aspects of pivotal trial design including psychosis as primary outcome
dementia with Lewy bodies (DLB)source ↗
▲FDA Feedback ReceivedCT1812FDA Meeting
FDA meeting to discuss Phase 2 results and registrational path for zervimesine in DLB psychosis
dementia with Lewy bodies with psychosissource ↗
▲Enrollment UpdateCT1812Trial
EAP enrolled 32 participants receiving zervimesine
dementia with Lewy bodiessource ↗
◆FDA Feedback ReceivedCT1812FDA Meeting
Productive discussions with FDA regarding registrational program for DLB psychosis
dementia with Lewy bodies (DLB) psychosissource ↗
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
◆FDA Feedback ReceivedCT1812FDA Meeting
FDA meeting scheduled to discuss next steps for registrational program in DLB psychosis
dementia with Lewy bodies psychosissource ↗
◆Timing GuidanceCT1812Presentation
FDA meeting minutes expected in Q2 2026
dementia with Lewy bodies psychosissource ↗
▲Poster PresentationCT1812Presentation
Poster presentation of zervimesine's impact on neuropsychiatric symptoms in DLB at AD/PD 2026
dementia with Lewy bodiessource ↗
●Type C MeetingCT1812FDA Meeting
Type C meeting with FDA regarding zervimesine for DLB psychosis
dementia with Lewy bodies psychosissource ↗
▲FDA Feedback ReceivedCT1812FDA Meeting
Received final minutes from FDA Type C meeting conducted on January 21, 2026
dementia with Lewy bodies (DLB) psychosissource ↗
▲Topline ReadoutCT1812Clinical Data
Phase 2 SHIMMER topline data: positive impact on neuropsychiatric symptoms (86% slowing of decline on NPI-12)
dementia with Lewy bodies (DLB)source ↗
◆FDA Feedback ReceivedCT1812FDA Meeting
FDA meeting minutes expected from Type C meeting
dementia with Lewy bodiessource ↗
●Type C MeetingCT1812FDA Meeting
Type C meeting with FDA to review Phase 2b study plans for zervimesine in DLB
dementia with Lewy bodiessource ↗
◆FDA Feedback ReceivedCT1812FDA Meeting
Receipt of meeting minutes from Type C meeting with FDA
dementia with Lewy bodiessource ↗
●Oral PresentationCT1812Presentation
Poster presentation at CTAD conference on Phase 3 plan
Alzheimer's diseasesource ↗
▲Enrollment CompleteCT1812Trial
START trial enrollment completed in December 2025
mild cognitive impairment and early Alzheimer's diseasesource ↗
▲Enrollment CompleteCT1812Trial
Completed enrollment of 540 participants in Phase 2 START Study
early Alzheimer's diseasesource ↗
▲FDA Feedback ReceivedCT1812FDA Meeting
Aligned with U.S. FDA on registrational path for zervimesine
Alzheimer's diseasesource ↗
●Other Regulator MilestoneCT1812Ex-US Regulatory
Expanded Access Program for dementia with Lewy bodies ongoing
dementia with Lewy bodiessource ↗
▲Topline ReadoutCT1812Clinical Data
SHIMMER topline results: consistent efficacy signals across behavioral, cognitive, functional, and motor domains
Dementia with Lewy Bodiessource ↗
▲Full ResultsCT1812Clinical Data
SHINE results: up to 108% slowing on assessments; robust response in lower tau cohort
Alzheimer's Diseasesource ↗
▲Patent GrantedCT1812IP / Competition
Intellectual property covering zervimesine (CT1812) through 2040 with patent term extension
▼Designation WithdrawnCT1812Designation
Breakthrough designation not granted by FDA for DLB; company will explore other expedited pathways
Dementia with Lewy Bodiessource ↗
▼Equity OfferingCorporate
Closed $30 million registered direct offering of 14,700,000 shares at $2.05 per share
▲Enrollment MilestoneCT1812Trial
Surpassed 50% enrollment in Phase 2 START study of zervimesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
◆End Of Phase 2 MeetingCT1812FDA Meeting
End-of-Phase 2 meeting with FDA regarding registrational plans for zervimesine in Alzheimer's disease
Alzheimer's diseasesource ↗
◆Oral PresentationCT1812Presentation
Podium presentation of SHIMMER study results at AAIC 2025
dementia with Lewy bodiessource ↗
◆Poster PresentationCT1812Presentation
Poster presentations on CSF and plasma biomarkers from SHINE study at AAIC 2025
Alzheimer's diseasesource ↗
▲Primary Endpoint MetCT1812Clinical Data
SHIMMER study met primary endpoint of safety and tolerability
dementia with Lewy bodiessource ↗
Past FDA Catalysts and PDUFA Decisions
How CGTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-31 | zervimesine (CT1812) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$131M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
1.5x
rNPV / MCap
Top 44%
Micro Cap(rank 290 of 658)
Percentile Rank
Cognition Therapeutics, Inc. faces pipeline headwinds (38/100), with $524M risk-adjusted pipeline value, led by CT1812 in Early Alzheimer's Disease (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CT1812 Small moleculeNCT05531656 | Early Alzheimer's Disease | Phase 2 | ACTIVE NOT_RECRUITING | 540 | May 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every CGTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Doyle John BrendanOfficer (Chief Financial Officer) | Disposition | -8,567 618,942 held | $1.28 | 05/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CGTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.1 % | 1.62 M | 1.20 M |
CGTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CGTX ranks across every disease it competes in
Competitive Position is a premium feature
See how CGTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCGTX News
CGTXCognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
Cognition Therapeutics has scheduled a Type C meeting with the FDA to discuss endpoints for its Phase 3 trial of zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). The meeting, set for October 20, 2026, will focus on aligning on the primary outcome related to psychosis symptoms. Zervimesine has previously demonstrated efficacy in reducing hallucinations and delusions in DLB patients.
Read more →CGTXCognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
Cognition Therapeutics, Inc. announced that CEO Lisa Ricciardi will present at the H.C. Wainwright Global Investment Conference on September 15, 2026. She will discuss the development of zervimesine, an investigational therapy for Alzheimer's disease and dementia with Lewy bodies. The presentation will be available via live webcast and later as a replay.
Read more →CGTXCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Cognition Therapeutics reported its financial results for Q2 2026, highlighting significant progress in its clinical programs. The company is preparing to initiate a Phase 3 trial for zervimesine targeting dementia with Lewy bodies psychosis in mid-2027. Additionally, a new patent for zervimesine enhances its intellectual property position. Despite a net loss, the company has sufficient funding to sustain operations into 2027.
Read more →CGTX▼ -6.4%on this news
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Cognition Therapeutics, Inc. will participate in a fireside chat at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. CEO Lisa Ricciardi will discuss the ongoing START study and the upcoming Phase 3 study of zervimesine (CT1812) for dementia with Lewy bodies psychosis. The event will be recorded and available on their website.
Read more →CGTX▼ -38.2%on this news
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
Cognition Therapeutics announced alignment with the FDA on key aspects of a pivotal trial for zervimesine (CT1812) targeting psychosis in dementia with Lewy bodies (DLB). The FDA considers DLB psychosis an approvable outcome, and the trial is set to begin in mid-2027. Zervimesine previously demonstrated significant improvements in psychosis symptoms during Phase 2 trials.
Read more →CGTXCognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
Cognition Therapeutics has announced the receipt of a Notice of Allowance from the USPTO for a new patent covering a polymorphic crystalline form of its lead candidate, zervimesine (CT1812). This patent will protect the formulation until 2045, with a possible extension to 2050. The new form is expected to enhance the drug's stability and efficacy in treating neurodegenerative disorders.
Read more →CGTXhttps://cogrx.com COGNITION THERAPEUTICS NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis 2 COGNITION
Cognition Therapeutics (CGTX) is focusing on the development of Zervimesine, an investigational oral therapy aimed at treating dementia with Lewy bodies (DLB) psychosis. The therapy has shown promising clinical results by providing significant benefits across multiple neuropsychological domains. As the company prepares for registrational development, they face various uncertainties and risks related to future trial outcomes and market competition.
Read more →CGTX▲ +5.9%on this newsshared move
Cognition Therapeutics Participating in Upcoming Investor Conferences
Cognition Therapeutics, Inc. announced that CEO Lisa Ricciardi will present at two upcoming investor conferences in June. The presentations will focus on the company's plans for a registration program in dementia with Lewy bodies (DLB) psychosis. Webcasts of the events will be available on the company's website.
Read more →CGTXCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
Cognition Therapeutics has completed a meeting with the FDA to discuss its investigational drug zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) and psychosis. During this meeting, the company reviewed data from its Phase 2 clinical study and outlined plans for a registrational program. The FDA's feedback was described as positive, marking progress in addressing DLB psychosis. CEO Lisa Ricciardi expressed optimism about moving forward following a formal review of the meeting notes expected in June.
Read more →CGTXCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics has received a second philanthropic donation to extend its expanded access program for zervimesine, an investigational therapy for dementia with Lewy bodies. This program, which has enrolled 32 participants, will provide two years of treatment. The company is also preparing to meet with the FDA to discuss future clinical trials for zervimesine.
Read more →CGTX▼ -5.7%on this newsshared move
Cognition Therapeutics Reports Financial Results for the First Quarter 2026
Cognition Therapeutics (CGTX) reported its financial results for Q1 2026 and announced a scheduled meeting with the FDA's Division of Psychiatry for May 20, 2026, to discuss registrational plans for zervimesine in treating dementia with Lewy body psychosis. The company anticipates topline results from a Phase 2 study in early Alzheimer's disease by 2027, which may guide further clinical development. Additionally, Cognition indicated that it has sufficient cash reserves to support its operations and capital expenditures through mid-2027, though it continues to operate at a loss.
Read more →CGTXCognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics is focusing on a faster approach to address psychosis in dementia with Lewy bodies (DLB) as it prepares for late-stage plans with Zervimesine. The article does not provide specific details about the drug's efficacy or timeline for the upcoming stages.
Read more →CGTXCognition Therapeutics to Present at Needham Virtual Healthcare Conference
Cognition Therapeutics, Inc. will present at the Needham Virtual Healthcare Conference on April 13, 2026. CEO Lisa Ricciardi will discuss the company's progress in developing treatments for Alzheimer's disease and dementia with Lewy bodies. The presentation will be available via live webcast and archived for 90 days. Cognition's lead candidate, zervimesine, has shown promise in Phase 2 trials.
Read more →CGTX▲ +17.4%on this newsshared move
Cognition Therapeutics CEO Issues Letter to Shareholders
Cognition Therapeutics' CEO Lisa Ricciardi shared a letter highlighting the company's advancements in developing zervimesine (CT1812) for dementia with Lewy bodies psychosis and Alzheimer's disease. The Phase 2 START trial is fully funded and expected to read out in late 2027. Positive results from previous trials support the ongoing development of zervimesine, with plans for future discussions with the FDA.
Read more →CGTXCognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
Cognition Therapeutics reported its financial results for 2025 and provided updates on its clinical development plans for zervimesine, particularly targeting dementia with Lewy bodies (DLB) psychosis. The company aims to meet with the FDA Division of Psychiatry in mid-2026 to discuss its registrational plan. Additionally, enrollment in the Phase 2 START trial for early Alzheimer's disease has been completed, with results expected in 2027.
Read more →CGTX▲ +5.6%on this newsshared move
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Cognition Therapeutics plans to release its financial results for Q4 and the full year 2025 on March 26, 2026. A conference call will follow to discuss these results and provide a business update. The company focuses on developing therapies for neurodegenerative disorders, with its lead candidate zervimesine showing promise in clinical trials.
Read more →CGTX▲ +6.5%on this news
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Cognition Therapeutics presented findings from the Phase 2 SHIMMER study on zervimesine at the AD/PD 2026 conference. The analysis highlighted zervimesine's effectiveness in slowing the decline of neuropsychiatric symptoms in dementia with Lewy bodies (DLB). The treatment showed promise for patients who cannot tolerate traditional antipsychotics, addressing a critical need in DLB care.
Read more →CGTXCognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Cognition Therapeutics is advancing zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) psychosis, following positive Phase 2 SHIMMER study results. The company plans to pursue a registrational path with the FDA, addressing a critical need as no approved treatments currently exist for DLB psychosis. Zervimesine has shown potential benefits without impairing motor function.
Read more →CGTXCognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics has extended its expanded access program for zervimesine (CT1812) in dementia with Lewy bodies, allowing for additional months of treatment. The program, which started in June 2025, has received positive feedback from participants regarding its operational aspects. The company aims to gather more long-term safety data while facilitating local monitoring by physicians. Zervimesine remains investigational and has not yet received regulatory approval.
Read more →CGTXCognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics held a Type C meeting with the FDA to discuss the Phase 2b study of zervimesine for dementia with Lewy bodies. The meeting focused on establishing clinically meaningful endpoints for the study. The company anticipates receiving the meeting minutes soon and aims to continue collaboration with the FDA. Zervimesine is an investigational drug that targets neurodegenerative disorders.
Read more →About Cognition Therapeutics, Inc.
Headquarters2500 WESTCHESTER AVE, PURCHASE, NY, 10577
BIOPHARMAWATCH ELITE PLUS
Trade the next CGTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime